Director Edward Neugeboren filed a Form 4 with the SEC on November 6, 2026, disclosing the grant of a stock option to purchase 5,000 shares of Matinas BioPharma Holdings, Inc. common stock.

Key Highlights

  • Grant date: November 6, 2026, the date of earliest transaction reported in the filing.
  • Option size: 5,000 shares of common stock (par value $0.0001 per share) granted under the 2025 Equity Incentive Plan.
  • Exercise price: $1.16 per share, with an expiration date of November 6, 2036.
  • Vesting terms: The option vests in full upon the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the Plan, subject to continued service.
  • Price paid: $0, as reported in the filing for the derivative security price.
  • Post-transaction holdings: 5,000 derivative securities beneficially owned following the reported transaction, held directly.

Stock Option Award to Director Edward Neugeboren at Matinas BioPharma

According to the Form 4 filed on November 6, 2026, Edward Neugeboren, identified as a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), received a stock option to purchase 5,000 shares of the company's common stock. The option was granted under the issuer's 2025 Equity Incentive Plan and carries an exercise price of $1.16 per share. The option is classified as a derivative security in Table II of the filing, with a transaction code of "A" indicating acquisition.

The filing states that the option will vest in full upon the earlier of two conditions: the one-year anniversary of the November 6, 2026 grant date, or a "Change in Control" as defined by the Plan. In either case, the filing notes that vesting is "subject to the Reporting Person's continued service through the applicable vesting date." The option has an expiration date of November 6, 2036, giving it a ten-year term from the grant date.

Following the reported transaction, Neugeboren beneficially owns 5,000 derivative securities directly, as reported in the filing. The Form 4 was signed by Jerome D. Jabbour as attorney-in-fact for Edward Neugeboren, also on November 6, 2026. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

Matinas BioPharma director Edward Neugeboren disclosed the receipt of a stock option covering 5,000 shares at an exercise price of $1.16, granted November 6, 2026 under the company's 2025 Equity Incentive Plan, with cliff vesting after one year or upon a Change in Control.